Phio Pharmaceuticals (NASDAQ:PHIO) and MusclePharm (OTCMKTS:MSLP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.
This table compares Phio Pharmaceuticals and MusclePharm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Phio Pharmaceuticals and MusclePharm’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Phio Pharmaceuticals||$140,000.00||38.39||-$7.36 million||($1.04)||-0.20|
|MusclePharm||$102.15 million||0.12||-$10.97 million||N/A||N/A|
Phio Pharmaceuticals has higher earnings, but lower revenue than MusclePharm.
This is a summary of recent ratings and price targets for Phio Pharmaceuticals and MusclePharm, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk & Volatility
Phio Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, MusclePharm has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.
Institutional & Insider Ownership
5.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 27.8% of MusclePharm shares are held by institutional investors. 2.3% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 60.7% of MusclePharm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
MusclePharm beats Phio Pharmaceuticals on 6 of the 8 factors compared between the two stocks.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
MusclePharm Company Profile
MusclePharm Corporation develops, manufactures, markets, and distributes nutritional supplements in the United States and internationally. It offers a range of powders, capsules, tablets, and gels. The company's MusclePharm brand product portfolio include Combat protein powder and Combat crunch protein bars; essentials supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products; and non-genetically modified organism sports performance products with organic ingredients, plant-based proteins, and natural caffeine sources for use in the various stages of the workout. It also provides FitMiss sports nutrition products, which are designed and formulated primarily for women lifestyle to cover various needs, including weight management, lean muscle mass, body composition, and general health and wellness. MusclePharm Corporation sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, as well as individuals who lead an active lifestyle. The company was founded in 2006 and is headquartered in Burbank, California.
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.